Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer. The...
16 KB (1,300 words) - 02:35, 16 July 2024
in 2010. In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.: 6, 23 ...
9 KB (798 words) - 07:15, 29 February 2024
afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib...
5 KB (232 words) - 10:23, 8 March 2024
anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab emtansine...
43 KB (4,651 words) - 13:41, 27 July 2024
1-1% frequency) Keratitis Interstitial lung disease Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits...
15 KB (1,122 words) - 15:16, 4 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
31 KB (3,428 words) - 11:40, 29 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
121 KB (13,799 words) - 03:46, 30 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
25 KB (2,086 words) - 02:24, 16 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
13 KB (1,177 words) - 16:45, 16 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
73 KB (6,429 words) - 05:45, 5 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
93 KB (8,776 words) - 07:12, 1 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,784 words) - 04:08, 6 January 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
10 KB (661 words) - 04:10, 26 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
149 KB (15,717 words) - 11:43, 7 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
20 KB (1,543 words) - 06:38, 10 March 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
46 KB (5,344 words) - 04:27, 29 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
21 KB (1,808 words) - 04:37, 20 March 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
10 KB (1,179 words) - 18:31, 8 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
6 KB (460 words) - 19:16, 8 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
40 KB (4,580 words) - 05:24, 3 June 2024
co-opted to promote cancer cell survival and metastasis. In breast cancers, neratinib, a novel pan-ERBB inhibitor, is able to downmodulate the amount of HER2...
63 KB (6,704 words) - 03:40, 6 August 2024
first-generation inhibitors, researchers have used irreversible EGFR inhibitors like neratinib or dacomitinib, called tyrosine kinase inhibitors (TKIs). These new drugs...
21 KB (2,160 words) - 02:06, 24 May 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
17 KB (1,708 words) - 13:56, 21 July 2024
expected to lead to a wider therapeutic index. The pan-ErbB inhibitor Neratinib was approved in the US in 2017 and in the EU in 2018 for the extended...
20 KB (2,061 words) - 05:47, 29 November 2023
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
27 KB (3,071 words) - 04:54, 3 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,122 words) - 03:21, 24 April 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
108 KB (12,653 words) - 16:16, 10 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
29 KB (2,696 words) - 14:16, 27 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,314 words) - 05:40, 9 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
24 KB (2,877 words) - 10:08, 2 June 2024